Lilly raises outlook for third time this year as Zepbound sales soar
MarketWatch · Thu, 29 Oct 2026 11:19:00 GMT
Read the full story at MarketWatch ↗OmniFin Portal's take
Excerpt from MarketWatch: “The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.”
Rule-based headline sentiment: Neutral
More Stocks headlines
President of the European Central Bank Christine Lagarde to step down. Here's who is tipped to replace her— CNBC MarketsCaterpillar’s stock heads for worst day in 7 years — and what that means for the Dow— MarketWatchDoorDash to acquire Instacart for $17 billion— CNBC MarketsAI build-out hits snag as Google and Microsoft put off raising capex forecasts— CNBC Markets